| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10,365.0 | 9,557.0 |
| Profit before tax | 4,686.0 | 3,921.0 |
| Net income | 3,864.0 | 3,216.0 |
| EPS (diluted, $ a share) | $7.08 | $5.93 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +20.1% |
|---|---|
| Revenue, year on year | +8.5% |
| Operating margin | 35.8% |
10-Q filed with the SEC, NASDAQ: AMGN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Amgen Inc: key numbers
- Share price
- $462.32Close, Nov 16
- Market cap
- $250B
- Shares outstanding
- 540.91MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Amgen Inc
All →Amgen Financial Results
Amgen reported third quarter 2026 financial results with total revenues increasing 8% year-over-year to $10.4 billion, driven by volume growth across its commercial portfolio. GAAP EPS rose 19% to $7.08, while the company generated $3.7 billion in free cash flow during the period.
- Term
- Q3 2026
“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise. The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.”
Robert A. Bradway, chairman and chief executive officer
Amgen Leadership Change
Amgen Inc. has appointed David W. Gibbs, the former CEO of Yum! Brands, to its Board of Directors, effective immediately. Mr. Gibbs will serve on the Audit and Compensation committees, bringing the total board size to 13 directors. He will receive the company's standard non-employee director compensation, including a pro-rated annual cash retainer and restricted stock units.